News

Romaco develops customer solutions for various forms of drug packaging and delivery systems and complex processing applications. DBAG Board of Management member Rolf Scheffell said in partnering with

The three new grants, combined with other grants renewed for 2011, brings total non dilutive R&D funding for 2011 to $4.8m, with an additional $3.3m committed for future

Currently, Lanxess is supplying specialty chemicals, color pigments to the Middle East customers for the construction industry and high-tech plastics and rubbers. The company has named Elie Saad

RE-LY is a PROBE (prospective, randomised, open-label with blinded endpoint evaluation), designed to compare two fixed doses of the oral direct thrombin inhibitor dabigatran (110mg and 150mg bid)

Sertech prepares patient instructional leaflets for its US pharmaceutical customers. The acquired company will immediately change its trading name to CCL Label. CCL Label manufactures similar products at

The ABSORB trial is a prospective, non-randomized (open label), two-phase study that recruited 131 patients from Australia, Belgium, Denmark, France, the Netherlands, New Zealand, Poland and Switzerland. Key

Dymista (also known as MP29-02 in clinical trials), is a nasal spray formulation for patients 12 years and older with seasonal allergic rhinitis. Efficacy and safety of Dymista

As per the terms of the agreement, Eisai is expected to get exclusive worldwide rights (excluding some countries) for the development and commercialization o f compound as well

The study is expected to show a clinically meaningful and significant reduction in overall mortality between the vaccine and control group and envisages enrolling about 800 subjects. The